Posted on

Psychedelics startups are on a long journey to consumer markets, but these 5 VCs are taking the ride


“Like a pressure cooker, COVID blew the lid off what was a simmering mental health crisis for over a decade,” VC Tim Schlidt told TechCrunch.
According to the World Health Organization, the global prevalence of anxiety and depression increased by a massive 25% in the first year of the pandemic. And when available treatment options showed their limits, both the general public and regulators became more willing to look into alternatives – including psychedelics.
Previously relegated to underground communities and rave culture, drugs like ketamine, MDMA (commonly known as ecstasy) and psilocybin are now being studied to develop therapies to treat everything from PTSD to cluster headaches.
“Today, there are 400+ ketamine clinics in the U.S., and over $200m has been raised over the last two years to open even more,” Dina Burkit …

Read More